ZOLINDA 15MG 30TAB

Indications

Approved Uses

Schizophrenia; Bipolar I disorder (acute manic/mixed episodes and maintenance); Adjunctive treatment of Major Depressive Disorder (adults); Irritability associated with autistic disorder (pediatric); Tourette’s disorder (pediatric).

Off-Label Uses

Common off-label uses include behavioral symptoms/agitation in dementia (not recommended routinely due to boxed warning), obsessive-compulsive disorder augmentation, anxiety/PTSD augmentation, and borderline personality disorder symptom-targeted use (evidence variable).

Dosage & Administration

Dosing by Condition

Adults-Schizophrenia: start 10-15 mg once daily; target/maintenance 15 mg daily; max 30 mg/day. Bipolar I acute mania/mixed: 15 mg once daily (monotherapy or adjunct), may increase; max 30 mg/day. Adjunctive MDD: start 2-5 mg once daily; usual range 2-15 mg/day; max 15 mg/day. Pediatric dosing exists for schizophrenia (13-17), bipolar I mania (10-17), autism irritability (6-17), and Tourette’s (6-18) per labeling.

Initial Dose

10-15mg once daily for schizophrenia or 15mg once daily for bipolar mania.

Maintenance Dose

15 mg once daily; range 10-30 mg/day depending on indication and response

Maximum Dose

30 mg per day

Children's Dosage

Schizophrenia (13-17 years): Initial 2mg/day, titrate to 10mg/day. Max 30mg/day. Bipolar I Disorder (10-17 years): Initial 2mg/day, titrate to 10mg/day. Max 30mg/day. Irritability with Autism (6-17 years): Initial 2mg/day, target 5-15mg/day. Tourette's (6-18 years): Initial 2mg/day, target 10-20mg/day.

Dose Adjustment Notes

Reduce aripiprazole dose with strong CYP2D6 inhibitors or strong CYP3A4 inhibitors; increase dose with strong CYP3A4 inducers; no adjustment generally required for renal impairment or mild-moderate hepatic impairment (use caution in severe hepatic impairment per labeling).

How to Take

Swallow tablet whole with water; may be taken with or without food; take once daily and preferably at the same time each day.

Side Effects

Common Side Effects

Headache, restlessness, akathisia, insomnia, nausea, vomiting, constipation, anxiety, dizziness, drowsiness, weight gain, increased salivation, blurred vision.

Side Effect Frequency

Very common (≥10%): akathisia, headache, insomnia. Common (1-10%): anxiety, restlessness/agitation, nausea, vomiting, constipation, dizziness, somnolence, tremor, fatigue, blurred vision, weight gain. Uncommon/Rare (<1%): orthostatic hypotension, tachycardia, seizures, neuroleptic malignant syndrome, tardive dyskinesia, hyperglycemia/diabetes mellitus, QT prolongation, agranulocytosis/leukopenia.

Safety & Warnings

Contraindications

Known hypersensitivity to aripiprazole or to any component/excipient of the formulation.

Warnings & Precautions

Key warnings/precautions: increased mortality in elderly with dementia-related psychosis; suicidality risk in children/adolescents/young adults when used with antidepressants; NMS; tardive dyskinesia; metabolic monitoring (weight, glucose, lipids); orthostatic hypotension/cardiovascular caution; seizures; leukopenia/neutropenia monitoring in at-risk patients; impulse-control/compulsive behaviors.

Age Restriction

Pediatric use is indication-specific: schizophrenia ≥13 years; bipolar I manic/mixed episodes ≥10 years; irritability associated with autistic disorder ≥6 years; Tourette’s disorder ≥6 years; not approved for major depressive disorder (adjunct) in pediatric patients.

Drug Interactions

Drug Interactions

Clinically significant interactions: strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine, quinidine) and strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) increase aripiprazole exposure → dose reduction; strong CYP3A4 inducers (e.g., carbamazepine, rifampin) decrease exposure → dose increase/avoid; additive hypotension/sedation with CNS depressants and antihypertensives.

Interaction Severity

MAJOR/clinically significant: strong CYP3A4 inhibitors, strong CYP2D6 inhibitors, strong CYP3A4 inducers (require dose adjustment/avoidance). MODERATE: additive CNS depression with alcohol/benzodiazepines/other sedatives; additive hypotension with antihypertensives. Other interactions (e.g., lithium/valproate) are generally not major pharmacokinetic interactions but monitor clinically.

Food Interaction

No restriction.

Special Populations

Pregnancy

Category C

Children

Schizophrenia (13-17 years): Initial 2mg/day, titrate to 10mg/day. Max 30mg/day. Bipolar I Disorder (10-17 years): Initial 2mg/day, titrate to 10mg/day. Max 30mg/day. Irritability with Autism (6-17 years): Initial 2mg/day, target 5-15mg/day. Tourette's (6-18 years): Initial 2mg/day, target 10-20mg/day.

Elderly

Start at lower doses, titrate slowly, and monitor carefully. Not approved for dementia-related psychosis due to increased mortality risk.

Kidney Impairment

No adjustment needed.

Liver Impairment

No dosage adjustment is required in hepatic impairment, including severe hepatic impairment (use usual clinical caution).

Storage & Patient Advice

Stopping the Medicine

Do not stop abruptly unless medically necessary; taper gradually under prescriber supervision.

Overdose

Overdose may cause somnolence/lethargy, vomiting, tremor, tachycardia, hypotension/hypertension, and rarely serious CNS/cardiac effects; management is supportive (airway/ventilation, cardiovascular monitoring, consider activated charcoal if early) and seek emergency care; no specific antidote.

Patient Counseling

Take once daily with or without food, ideally at the same time daily; avoid alcohol and use caution driving until effects known; rise slowly to reduce dizziness; do not stop abruptly without prescriber advice; report suicidal thoughts/behavior changes, uncontrolled movements/akathisia, signs of hyperglycemia, and new impulse-control urges (e.g., gambling); keep follow-ups for metabolic and movement-disorder monitoring and review all concomitant medicines.

Monitoring Requirements

Baseline and periodic: weight/BMI (± waist circumference), blood pressure, fasting glucose or HbA1c, fasting lipids; assess for extrapyramidal symptoms/tardive dyskinesia (e.g., AIMS), akathisia, and clinical response/suicidality; consider CBC if history of low WBC/leukopenia; monitor for impulse-control problems.

Pharmacology

Mechanism of Action

Partial agonist at dopamine D2 (and D3) and serotonin 5‑HT1A receptors; antagonist at serotonin 5‑HT2A receptors.

Onset of Action

Pharmacologic effects begin within hours after a dose; clinical improvement may be seen within 1-2 weeks, with full effect often taking 4-6 weeks depending on indication.

Duration of Effect

Approximately 24 hours per dose (supports once-daily dosing); therapeutic symptom control is maintained with continued daily use.

Half-Life

Aripiprazole: ~75 hours. Dehydro-aripiprazole (active metabolite): ~94 hours.

Metabolism

Extensive hepatic metabolism primarily via CYP2D6 and CYP3A4 to an active metabolite (dehydro-aripiprazole).

Product Information

Available Dosage Forms

Aripiprazole is available (globally) as oral tablets, orally disintegrating tablets, oral solution, short-acting IM injection, and long-acting injectable formulations (IM extended-release).

Composition per Dose

Each tablet: 15 mg aripiprazole

Generic Availability

Yes

OTC Alternatives

No OTC alternative

Psych Class

Antipsychotic-Atypical

Controlled Substance

No

Legal Disclaimer - Al Mujtama Pharmacy

The product information provided is derived from verified pharmaceutical references and is intended for general health education only. It is not a substitute for professional medical advice, diagnosis, or treatment.

Al Mujtama Pharmacy assumes no legal or medical liability for:

• Any therapeutic decision made based on the information displayed without consulting a licensed physician or pharmacist
• Any discrepancy between the information provided and the product's package insert or SFDA guidelines
• Any misuse of medication resulting from personal interpretation of the content displayed

Important notice: Drug formulations and instructions may vary between production batches. Always rely on the leaflet included inside the product packaging you have, and consult your pharmacist or physician before starting, adjusting, or discontinuing any medication.

By using this content, you acknowledge that you have read this disclaimer and agree that Al Mujtama Pharmacy bears no liability arising from reliance on this information as a substitute for direct medical consultation.

Your health is a trust - always consult your doctor first.